Prior to acquisition, the company then named Cellular Dynamics International, Inc. tendered an initial public offering in July 2013 under the ticker symbol ICEL.

On March 30, 2015, Fujifilm Holdings Corporation announced an agreement to acquire Cellular Dynamics International for $307 million or $16.50/share on a fully diluted basis.

In 2013, FCDI was awarded a US$16,000,000 contract from the California Institute for Regenerative Medicine to reprogram and bank iPS cells from 3,000 individuals.

The company's iCell and MyCell cells are readily adapted to screening platforms and demonstrate functionality using widely accepted readout technologies.

[12] FCDI's products are used in high throughput screens,[13] and have been used as supporting data in Investigational New Drug (IND) submissions to the FDA.

Specifically in the area of tissue engineering, FCDI's iCell and MyCell products are being employed across a variety of technologies, such as implantable devices, de-cellularized organ reconstitution and 3D bioprinting.

In 2013, CIRM awarded FCDI a US$16,000,000 grant to derive 3 iPS cell lines from each of 3,000 donors that represent a multitude of disease states.

[4] This project follows a $6.3 million grant awarded by the National Heart, Lung, and Blood Institute to FCDI and the Medical College of Wisconsin to investigate the mechanisms underlying left ventricular hypertrophy.

[16][17] FCDI's role in this project is to generate iPS cell lines and cardiomyocytes from 250 donors selected from the Hypertension Genetic Epidemiology Network (HyperGEN) GWAS study.